RT Journal Article
SR Electronic
T1 Characterizing clinical progression of COVID-19 among patients in Shenzhen, China: an observational cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.22.20076190
DO 10.1101/2020.04.22.20076190
A1 Bi, Qifang
A1 Hong, Chengcheng
A1 Meng, Juan
A1 Wu, Zhenke
A1 Zhou, Pengzheng
A1 Ye, Chenfei
A1 Sun, Binbin
A1 Kucirka, Lauren M.
A1 Azman, Andrew S.
A1 Wang, Tong
A1 Chen, Jiancong
A1 Wang, Zhaoqin
A1 Liu, Lei
A1 Lessler, Justin
A1 Edwards, Jessie K.
A1 Ma, Ting
A1 Zhang, Guoliang
YR 2020
UL http://medrxiv.org/content/early/2020/05/13/2020.04.22.20076190.abstract
AB Background Understanding clinical progression of COVID-19 is a key public health priority that informs resource allocation during an emergency. We characterized clinical progression of COVID-19 and determined important predictors for faster clinical progression to key clinical events and longer use of medical resources.Methods and Findings The study is a single-center, observational study with prospectively collected data from all 420 patients diagnosed with COVID-19 and hospitalized in Shenzhen between January 11th and March 10th, 2020 regardless of clinical severity. Using competing risk regressions according to the methods of Fine and Gray, we found that males had faster clinical progression than females in the older age group and the difference could not be explained by difference in baseline conditions or smoking history. We estimated the proportion of cases in each severity stage over 80 days following symptom onset using a nonparametric method built upon estimated cumulative incidence of key clinical events. Based on random survival forest models, we stratified cases into risk sets with very different clinical trajectories. Those who progressed to the severe stage (22%,93/420), developed acute respiratory distress syndrome (9%,39/420), and were admitted to the intensive care unit (5%,19/420) progressed on average 9.5 days (95%CI 8.7,10.3), 11.0 days (95%CI 9.7,12.3), and 10.5 days (95%CI 8.2,13.3), respectively, after symptom onset. We estimated that patients who were admitted to ICUs remained there for an average of 34.4 days (95%CI 24.1,43.2). The median length of hospital stay was 21.3 days (95%CI, 20.5,22.2) for cases who did not progress to the severe stage, but increased to 52.1 days (95%CI, 43.3,59.5) for those who required critical care.Conclusions Our analyses provide insights into clinical progression of cases starting early in the course of infection. Patient characteristics near symptom onset both with and without lab parameters have tremendous potential for predicting clinical progression and informing strategic response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGZ was funded by the National Science and Technology Major Project for Control and Prevention of Major Infectious Diseases of China (No. 2017ZX10103004). CH, PZ, CY, BS, TW, JC, TM were funded by the Emergency Response Program of Harbin Institute of Technology (HITERP010) and Emergency Response Program of Peng Cheng Laboratory (PCLERP001). JL and QB were funded by a grant from the US Centers for Disease Control and Prevention (NU2GGH002000). Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of the study are not publicly available. Summary data may be available from the authors upon reasonable request with permission from Shenzhen Third People's Hospital.